PANDAS/PANS is a clinically distinct entity and needs early and prompt immunotherapy
Treatment of CIDP: immunoglobulins or steroids first?
New regulatory-approved medications should be used exclusively for prevention of attacks of NMOSD over (current used) non-regulatory approved medications
NMOSD attacks should be treated with apheresis/plasma exchange at first presentation, either with or without corticosteroids
2015 International Panel criteria for NMOSD are outdated and should be replaced with a diagnostic classification primarily based on autoantibody status rather than clinical presentation (e.g. AQP4 disease, MOG disease)